ZA932455B - Method of treating cancer by conjunctive therapy wit 2'-halomethylidene derivatives and a S-phase ir M-phase specific antineoplastic agent - Google Patents

Method of treating cancer by conjunctive therapy wit 2'-halomethylidene derivatives and a S-phase ir M-phase specific antineoplastic agent

Info

Publication number
ZA932455B
ZA932455B ZA932455A ZA932455A ZA932455B ZA 932455 B ZA932455 B ZA 932455B ZA 932455 A ZA932455 A ZA 932455A ZA 932455 A ZA932455 A ZA 932455A ZA 932455 B ZA932455 B ZA 932455B
Authority
ZA
South Africa
Prior art keywords
phase
wit
treating cancer
antineoplastic agent
conjunctive therapy
Prior art date
Application number
ZA932455A
Other languages
English (en)
Inventor
Sai P Sunkara
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of ZA932455B publication Critical patent/ZA932455B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA932455A 1992-04-10 1993-04-05 Method of treating cancer by conjunctive therapy wit 2'-halomethylidene derivatives and a S-phase ir M-phase specific antineoplastic agent ZA932455B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86639992A 1992-04-10 1992-04-10

Publications (1)

Publication Number Publication Date
ZA932455B true ZA932455B (en) 1993-10-20

Family

ID=25347526

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA932455A ZA932455B (en) 1992-04-10 1993-04-05 Method of treating cancer by conjunctive therapy wit 2'-halomethylidene derivatives and a S-phase ir M-phase specific antineoplastic agent

Country Status (17)

Country Link
US (2) US20040102461A1 (fr)
EP (1) EP0664708B1 (fr)
JP (1) JP3713668B2 (fr)
KR (1) KR100258668B1 (fr)
AT (1) ATE170077T1 (fr)
AU (1) AU667527B2 (fr)
CA (1) CA2117891C (fr)
DE (1) DE69320646T2 (fr)
DK (1) DK0664708T3 (fr)
ES (1) ES2123642T3 (fr)
HU (1) HU219476B (fr)
IL (1) IL105329A (fr)
MX (1) MX9302038A (fr)
NZ (1) NZ251211A (fr)
TW (1) TW362971B (fr)
WO (1) WO1993020825A1 (fr)
ZA (1) ZA932455B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996001638A1 (fr) * 1994-07-11 1996-01-25 Hoechst Marion Roussel, Inc. Procede de traitement du stade neoplasique d'une affection par therapie associant des derives de 2'-fluorometylidene et une radiotherapie ou chimiotherapie
WO1996001834A1 (fr) * 1994-07-12 1996-01-25 Yamasa Corporation 2'-desoxy-2'-(methylidene substitue ou non substitue)-4'-thionucleoside
EP2246058A1 (fr) 1997-09-04 2010-11-03 Novoneuron, Inc. Noribogain utilisée pour le traitement de la douleur et de la toxicomanie
US7220737B1 (en) 1997-09-04 2007-05-22 Novoneuron, Inc Noribogaine in the treatment of pain and drug addiction
US6544962B1 (en) 2000-11-02 2003-04-08 Matrix Pharmaceutical, Inc. Methods for treating cellular proliferative disorders
KR20040094692A (ko) * 2002-02-14 2004-11-10 파마셋, 리미티드 변형된 불소화 뉴클레오사이드 유사체
AU2003280867A1 (en) * 2002-11-04 2004-06-07 Charite-Universitatsme Dizin Berlin Specific haplotypes of the mdr1 gene and their use in diagnosis and therapy
US9394294B2 (en) 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8362007B1 (en) 2010-05-11 2013-01-29 Demerx, Inc. Substituted noribogaine
US8765737B1 (en) 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8637648B1 (en) 2010-06-22 2014-01-28 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
US9358237B2 (en) 2010-07-23 2016-06-07 Demerx, Inc. Noribogaine compositions
EP2481740B1 (fr) 2011-01-26 2015-11-04 DemeRx, Inc. Procédés et compositions pour préparer de la noribogaïne à partir de voacangine
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
WO2013085922A1 (fr) 2011-12-09 2013-06-13 Demerx, Inc. Esters phosphoriques de noribogaïne
SG11201402826YA (en) 2011-12-22 2014-12-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
US9150584B2 (en) 2012-01-25 2015-10-06 Demerx, Inc. Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
US8877921B2 (en) 2012-01-25 2014-11-04 Demerx, Inc. Synthetic voacangine
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
JP2016508979A (ja) 2012-12-20 2016-03-24 デメレックス， インコーポレイテッド 置換ノルイボガイン
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
WO2015195673A2 (fr) 2014-06-18 2015-12-23 Demerx, Inc. Dérivés d'indole et de benzofurane halogénés d'isoquinuclidène et procédés pour leur préparation.

Also Published As

Publication number Publication date
DE69320646T2 (de) 1999-01-14
HU9402914D0 (en) 1995-01-30
CA2117891A1 (fr) 1993-10-28
HU219476B (hu) 2001-04-28
US20050032738A1 (en) 2005-02-10
MX9302038A (es) 1993-10-01
AU3813193A (en) 1993-11-18
KR100258668B1 (ko) 2000-07-01
KR950700749A (ko) 1995-02-20
ES2123642T3 (es) 1999-01-16
EP0664708B1 (fr) 1998-08-26
AU667527B2 (en) 1996-03-28
HUT71224A (en) 1995-11-28
ATE170077T1 (de) 1998-09-15
DK0664708T3 (da) 1998-11-02
NZ251211A (en) 1997-05-26
EP0664708A4 (fr) 1995-04-24
WO1993020825A1 (fr) 1993-10-28
JPH07505653A (ja) 1995-06-22
EP0664708A1 (fr) 1995-08-02
DE69320646D1 (de) 1998-10-01
IL105329A0 (en) 1993-08-18
US20040102461A1 (en) 2004-05-27
TW362971B (en) 1999-07-01
IL105329A (en) 1998-06-15
JP3713668B2 (ja) 2005-11-09
CA2117891C (fr) 1998-07-07

Similar Documents

Publication Publication Date Title
ZA932455B (en) Method of treating cancer by conjunctive therapy wit 2'-halomethylidene derivatives and a S-phase ir M-phase specific antineoplastic agent
EG19642A (en) A process for the preparation of oral composition for the treatment of inflammatory bowel diseases
GEP20002146B (en) Therapeutic Peptide Derivatives
EP0460912A3 (en) Medicaments for the treatment of sexual disorder
IL114530A0 (en) Method of treating a neoplastic disease state by conjunctive therapy with 2'-fluoromethylidene derivatives and radiation or chemotherapy
CA2108963A1 (fr) Compositions et methodes de traitement et de prevention du cancer, du sida et de l'anemie
IL101245A0 (en) Pharmaceutical compositions for the treatment of prostatic cancer
EP0584034A3 (fr) Conjugués de médicaments cytotoxiques pour le traitement de maladies néoplastiques.
GR3023645T3 (en) Treatment of liver cancer
NZ303993A (en) Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders
AU1898792A (en) Treatment or therapeutic booth for energetic, cosmetic and medical purposes
HU9402816D0 (en) Medicament for the treatment of airways inflammation and airways hyperresponsiveness
DE3163920D1 (en) Pharmaceutical preparations comprising polyprenyl compounds, especially as anti-cancer agents, and pharmaceutical compositions for the prevention and treatment of cancer and skin diseases
NZ268039A (en) Use of efaroxan in treating parkinson's disease
AU4042795A (en) Treatment of non-small cell lung carcinoma
CA2103708A1 (fr) Traitement du cancer de l'ovaire
IL117465A (en) Use of certain cystine derivatives for the preparation of a medicament for the treatment of restenosis
NO943795L (no) Metode for behandling av kreft ved konjunktiv terapi med 2'-halomethylidenderivater og et S-fase eller M-fase-spesifikt antineoplastisk middel
GB9024181D0 (en) Pharmaceutical compositions and methods for the treatment of malignancy
HU904161D0 (en) Medical preparations for treating asthmatic and other diseases attacking the respiratory organs
GB9123572D0 (en) Pharmaceutical compositions and methods for the treatment of malignancy
IL94263A0 (en) Therapeutic compositions for the treatment or prevention of snoring
HU903177D0 (en) Medical preparation for treating keratoconical changes of the cornea
IT1264428B1 (it) Composizioni farmaceutiche per il trattamento della psoriasi